U.S. drugmaker Pfizer Inc. signed a deal with Germany’s BioNTech SE to co-develop a potential vaccine for the coronavirus using BioNTech’s mRNA-based drug development platform, the companies said on Tuesday.
Celltex Therapeutics Corporation began active discussions with the FDA regarding a study using using adult, autologous Mesenchymal Stem Cells against coronavirus (COVID-19)-type symptoms.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Inside the United States, the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 begins today. The mRNA-1273 vaccine is being developed by Moderna Therapeutics with the National Institute of Allergy and Infectious Disease (NIAID).
Pfizer and EMD Serono, the biopharmaceutical division of Merck KGaA, jointly announced that their Phase III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with chemoradiotherapy (CRT) for untreated locally advanced squamous cell carcinoma of the head and neck was unlikely to hit the primary endpoint.
As COVID-19 spreads across the globe, Vancouver-based AbCellera and Eli Lilly teamed up to co-develop antibody products for the treatment and prevention of the novel coronavirus.
Canada’s Medicago announced the successful production of a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene. The company is focused on developing a vaccine for COVID-19, the virus caused by SARS-CoV-2.
AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.
Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.
France-based MedDay Pharmaceuticals announced the company’s MED1003 failed to meet the primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).
